U. S. Securities and Exchange Commission
                         Washington, D. C.  20549

                                FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period ended September 30, 2006

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the transition period from                to
                                    --------------    ---------------

                     Commission File No.  000-31377

                          REFLECT SCIENTIFIC, INC.
                          ------------------------
              (Name of Small Business Issuer in its Charter)

             UTAH                                      87-0642556
             ----                                      ----------
  (State or Other Jurisdiction of              (I.R.S. Employer I.D. No.)
 incorporation or organization)

                          1270 South 1380 West
                            Orem, Utah 84058
                            ----------------
                  (Address of Principal Executive Offices)

                 Issuer's Telephone Number:  (801) 226-4100
                                             --------------

                         970 Terra Bella Avenue
                     Mountain View, California, 94043
                     --------------------------------
                          Former Name or Address

Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.

(1)  Yes  X     No                 (2)  Yes  X    No
         ---     ---                        ---     ---

Indicate by check mark whether the Registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).  Yes     No X
                                        ---    ---

<PAGE>
             Applicable Only to Issuers Involved in Bankruptcy
                Proceedings During the Preceding Five Years

Not applicable.

                   Applicable Only to Corporate Issuers

Indicate the number of shares outstanding of each of the Registrant's classes
of common stock, as of the latest practicable date: September 30, 2006 -
30,618,502 shares of common stock.


Transitional small business disclosure format (check one):  Yes    No X
                                                               ---   ---

                      PART I - FINANCIAL INFORMATION

Item 1.   Financial Statements.
-------------------------------

          The Financial Statements of the Company required to be filed with
this 10-QSB Quarterly Report were prepared by management, and commence on the
following page, together with Related Notes.  In the opinion of management,
the Financial Statements fairly present the financial condition of the
Company.
<PAGE>
                    REFLECT SCIENTIFIC, INC.

                CONSOLIDATED FINANCIAL STATEMENTS

                     September 30, 2006
<PAGE>
                    REFLECT SCIENTIFIC, INC.
                   Consolidated Balance Sheets

                              ASSETS

                                                   September 30,
                                                       2006
                                                    (Unaudited)
CURRENT ASSETS

     Cash                                            $   113,653
     Accounts receivable,(net)                           447,160
     Inventory, net                                      377,105
     Prepaid expenses                                     14,363
                                                     -----------
          Total Current Assets                           952,281
                                                     -----------
FIXED ASSETS (NET)                                       195,449
                                                     -----------
OTHER ASSETS

     Intangible assets (net)                           5,429,055
     Income tax receivable                                24,761
     Deposits                                              5,350
                                                     -----------
          Total other assets                           5,459,166
                                                     -----------
          TOTAL ASSETS                               $ 6,606,896
                                                     ===========

The accompanying notes are an integral part of these consolidated financial
statements.
                                2
<PAGE>
                    REFLECT SCIENTIFIC, INC.
             Consolidated Balance Sheets (Continued)


               LIABILITIES AND SHAREHOLDERS' EQUITY

                                                   September 30,
                                                       2006
                                                    (Unaudited)
CURRENT LIABILITIES

     Notes payable                                   $    303,765
     Accounts payable                                     239,052
     Accrued expenses                                      96,958
     Customer deposits                                     36,504
     Income taxes payable                                     400
                                                     ------------
          Total Current Liabilities                       676,679
                                                     ------------
NON-CURRENT LIABILITIES

     Deferred income taxes                                 32,676
                                                     ------------
          Total Liabilities                               709,355
                                                     ------------
COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY

     Preferred stock, $0.01 par value,
     authorized 5,000,000 shares; 10,000
     shares issued and outstanding                            100
     Common stock, $0.01 par value, authorized
     50,000,000 shares; 30,672,177 shares issued
     and outstanding                                      306,722
     Additional paid-in capital                         7,036,665
     Accumulated deficit                               (1,445,946)
                                                    -------------
          Total Shareholders' Equity                    5,897,541
                                                    -------------
          TOTAL LIABILITIES AND SHAREHOLDERS'
          EQUITY                                    $   6,606,896
                                                    =============

The accompanying notes are an integral part of these consolidated financial
statements.
                                3
<PAGE>
                    REFLECT SCIENTIFIC, INC.
              Consolidated Statements of Operations
                           (Unaudited)

                          For the Three Months Ended For the Nine Months Ended
                               September 30,              September 30,
                           2006                2005     2006            2005

REVENUES                    $ 652,359     $ 573,572   $ 1,907,540 $1,628,313

COST OF GOODS SOLD            417,351       326,041     1,177,137    919,883
                             --------     ---------   ----------- ----------
GROSS PROFIT                  235,008       247,531       730,403    708,430
                             --------     ---------   ----------- ----------
OPERATING EXPENSES

     Salaries and wages       252,625        88,784       475,782    250,131
     Payroll taxes             20,755         7,803        42,012     21,416
     Rent expense              11,869        21,454        50,530     59,761
     General and
      administrative expense  724,569        72,490     1,053,099    322,921
                            ---------     ---------   ----------- ----------
   Total Operating Expenses 1,009,818       190,531     1,621,423    654,229
                            ---------     ---------   ----------- ----------
OPERATING INCOME (LOSS)      (774,810)       57,000      (891,020)    54,201
                             --------     ---------   ----------- ----------
OTHER EXPENSE

     Interest expense               -        (1,583)          (25)    (9,961)
                             --------     ---------   ----------- ----------
          Total Other Expense       -        (1,583)          (25)    (9,961)
                             --------     ---------   ----------- ----------
NET INCOME (LOSS) BEFORE
INCOME TAX                   (774,810)       55,417      (891,045)    44,240
                             --------     ---------   ----------- ----------
INCOME TAX EXPENSE                  -             -             -          -

NET INCOME (LOSS)           $(774,810)    $  55,417   $  (891,045)$   44,240
                             ========     =========   =========== ==========
Preferred distribution,
dividends                           -      (108,054)            -   (700,000)

NET LOSS PER SHARE APPLICABLE
TO COMMON SHAREHOLDERS      $(774,810)    $ (52,637)  $  (891,045)$ (655,759)
                            =========     =========   =========== ==========
EARNINGS PER SHARE          $   (0.03)    $   (0.00)  $     (0.03)$    (0.03)
                             ========     =========   =========== ==========
WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING          30,156,174   24,380,000    27,124,903 24,204,615
                             ==========  ==========   =========== ==========


The accompanying notes are an integral part of these consolidated financial
statements.
                                4
<PAGE>
                      REFLECT SCIENTIFIC, INC.
         Consolidated Statements of Shareholder's Equity


                                                        Additional
                    Preferred Stock   Common Stock       Paid-in    Retained
                    Shares   Amount  Shares    Amount    Capital    Earnings
Balance,
December 31, 2005    10,000     100  25,530,002  255,300  1,210,337  (554,901)

Common stock issued
for cash (unaudited)      -       -     400,000    4,000    316,000         -

Common stock issued
pursuant to merger
with Cryomaster
(unaudited)               -       -   3,000,000   30,000  3,720,000         -

Common stock issued
pursuant to JM
SciTech, LLC
purchase
(unaudited)               -       -     200,000    2,000    338,000         -

Common stock issued
for cash (unaudited)      -       -   1,073,500   10,735  1,062,765         -

Common stock issued
for services
(unaudited)               -       -     415,000    4,150    390,100         -

Common stock issued
for commissions
(unaudited)               -       -      53,675      537     52,065         -

Stock offering costs
(Unaudited)               -       -           -        -    (52,602)        -
Net loss for the
quarter ended
September 30, 2006
(unaudited)               -       -           -        -          -  (891,045)
                   --------   -----  ----------  -------  ---------  --------
Balances,
September 30, 2006
(unaudited)          10,000  $  100  30,672,177 $306,722$7,036,665$(1,445,946)
                   ======== =======  ==========  =======  ======== ==========


The accompanying notes are an integral part of these consolidated financial
statements.
                                5
<PAGE>

                    REFLECT SCIENTIFIC, INC.
              Consolidated Statements of Cash Flows
                           (Unaudited)

                                            For the Nine Months Ended
                                                    September 30,
                                              2006                2005
CASH FLOWS FROM OPERATING ACTIVITIES

     Net income (loss)                    $  (891,045)    $    44,240
     Adjustments to reconcile net income
      to net cash provided by operating
      activities:
          Depreciation                         33,891           2,474
          Amortization                         15,850             700
          Common stock issued for services    394,250           9,056
     Changes in operating assets and
     liabilities:
         Increase in accounts receivable     (129,886)        (54,129)
         Increase in inventory                (71,421)        (93,133)
         Increase in income tax receivable    (24,761)              -
         Increase in prepaid asset            (10,000)              -
         Increase in accounts payable and
          accrued expenses                    170,703          40,675
                                           ----------     -----------
               Net Cash Used by
               Operating Activities          (512,419)        (50,117)
                                           ----------     -----------
CASH FLOWS FROM INVESTING ACTIVITIES

   Cash paid for fixed assets                (208,390)              -
   Cash paid for intangible assets         (1,354,905)              -
                                           ----------     -----------
               Net Cash Used by
               Investing Activities        (1,563,295)              -
                                           ----------     -----------
CASH FLOWS FROM FINANCING ACTIVITIES

     Change in long term line of credit             -        (269,036)
     Notes payable                            303,765               -
     Proceeds from common stock issuance    1,393,500               -
     Proceeds from preferred stock issuance         -         700,000
                                           ----------     -----------
               Net Cash Provided by
               Financing Activities         1,697,265         430,964
                                           ----------     -----------
NET INCREASE (DECREASE) IN CASH              (378,449)        380,847

CASH AT BEGINNING OF PERIOD                   492,102          80,739
                                           ----------     -----------
CASH AT END OF PERIOD                      $  113,653     $   461,586
                                           ==========     ===========

SUPPLEMENTAL CASH FLOW INFORMATION:

     Cash Paid For:

          Interest                         $       25     $     9,961
          Income taxes                     $        -     $         -

NON-CASH FINANCING ACTIVITIES:

     Common stock issued for services      $  446,852     $     9,056


The accompanying notes are an integral part of these consolidated financial
statements.
                                6
<PAGE>
                    REFLECT SCIENTIFIC, INC.
          Notes to the Consolidated Financial Statements
             September 30, 2006 and December 31, 2005


NOTE 1 -  BASIS OF FINANCIAL STATEMENT PRESENTATION

     The accompanying unaudited condensed financial statements have been
     prepared by the Company pursuant to accounting principles generally
     accepted in the United States of America. Certain information and
     footnote disclosures normally included in financial statements prepared
     in accordance with accounting principles generally accepted in the
     United States of America have been condensed or omitted in accordance
     with such rules and regulations.  The information furnished in the
     interim condensed financial statements include normal recurring
     adjustments and reflects all adjustments, which, in the opinion of
     management, are necessary for a fair presentation of such financial
     statements.  Although management believes the disclosures and
     information presented are adequate to make the information not
     misleading, it is suggested that these interim condensed financial
     statements be read in conjunction with the Company's most recent audited
     financial statements and notes thereto included in its December 31, 2005
     financial statements.  Operating results for the nine months ended
     September 30, 2006 are not necessarily indicative of the results that may
     be expected for the year ending December 31, 2006.

NOTE 2 -  ACQUISITIONS

     Effective April 19, 2006, the Company entered into a merger agreement
     with Cryomastor Inc.   As part of this agreement, the Company received
     assets valued at the following:

                 Patents                      $     3,081,777
                 Customer Lists                       480,000
                 Goodwill                           1,289,799
                                              ---------------
                                              $     4,851,576
                                              ===============

     As consideration for these assets, the Company issued 3,000,000 shares
     at $1.25 of its common stock that are restricted securities to the
     shareholders of Cryomastor, Inc. as well as paid $700,000 to the same
     shareholders.  The Company also advanced $300,000 to be utilized for the
     operations of Cryomastor, Inc. and were required to pay a $300,000 debt
     of Cryomastor, Inc. for a U.S. patent of Cryomastor systems within 90
     days of the closing on June 27, 2006, or on or about September 25, 2006.
     An employment agreement will be executed and the Company will pay to the
     Cryomastor shareholders 2.5% of the gross annual revenue earned by the
     Company.

     As part of the execution and delivery of the Merger Agreement, the
     Company offered a minimum of 1,000,000 shares of common stock at $1 per
     share to accredited investors.  To date the Company has sold 1,073,500 of
     these shares.

                                7
<PAGE>
                    REFLECT SCIENTIFIC, INC.
          Notes to the Consolidated Financial Statements
               September 30, 2006 and December 31, 2005


NOTE 2 -  ACQUISITIONS (continued)

     The Company acquired Cryomaster because the business was synergistic
     with the Company as they both serve the Biotech industry.  The business
     offers a growth opportunity for the Company because of products that can
     fill a market need.

     Effective April 4, 2006, the Company entered into an agreement to
     purchase JM SciTech, LLC.  Pursuant to this agreement, the Company
     purchased and JM SciTech, LLC sold all rights, title and interest in and
     to the JMST Technology.  This resulted in the Company obtaining assets
     valued as follows:

                    Intangible assets        $       350,000
                    Goodwill                         240,000
                                             ---------------
                                             $       590,000
                                             ===============

     As consideration for the JMST Technology, the Company issued 200,000
     shares at $1.70 of its common stock that are restricted securities, paid
     the sum of $250,000, and will pay certain royalty payments as outlined in
     the agreement.  As part of this agreement, the Company issued 400,000
     shares of common stock that are "restricted securities" as defined in
     Rule 144 to "accredited investors" only, to finance the acquisition of JM
     SciTech, LLC.  These shares were sold at a price of $0.80 per share.
     None of these shares were accorded registration rights of any kind.

     The Company acquired JMST because the business was synergistic with the
     Company as they both serve the Biotech industry.  The business offered a
     strong growth opportunity, a successful business model, ongoing sales,
     innovation and four patents.

NOTE 3 -  SUBSEQUENT EVENTS

     Effective August 3, 2006, the Company signed a Letter of Intent to
     purchase All Temp Engineering.  As consideration for the purchase, the
     Company will issue 2,000,000 shares of its common stock that are
     restricted securities and pay certain royalties to its shareholders.  As
     of September 30, 2006, the purchase had not yet been completed.

     Effective August 23, 2006, the Company signed a Letter of Intent to
     purchase Smithgall & Associates, Inc., dba Image Labs International.  As
     consideration for the purchase, the Company will issue 525,000 shares of
     its common stock that are restricted securities; pay $200,000; pay
     certain royalties on certain of Image Labs business segments to this
     shareholder; and will employ Image Labs sole shareholder. Simultaneously,
     the Company signed another Letter of Intent to employ another person
     associated with a business segment of Image Labs; paid the associated
     person $37,500 on the signing of that Letter of Intent; will pay that
     person certain royalties on another business segment of Image Labs; and
     has agreed to issue 500,000 shares of its common stock that are
     restricted securities. As of September 30, 2006, the purchase of Image
     Labs had not yet been completed.

     The due date of the $300,000 Note assumed by the Company in the
     Cryomastor acquisition was extended from September 25, 2006, to December
     31, 2006.




                                8
<PAGE>
Item 2.   Management's Discussion and Analysis or Plan of Operation.
--------------------------------------------------------------------

Results of Operations.
----------------------

          Our revenues increased during the quarter ended September 30, 2006,
to $652,359, from $573,572 for the quarter ended September 30, 2005, primarily
as a result of a general improvement in sales across several product lines.

          Our cost of goods increased in the quarter ended September 30, 2006,
as compared to September 30, 2005, to $417,351 from $326,041, as a result of
increased raw material costs and increased sales.

          General and administrative expenses increased to $724,569 during the
quarter ended September 30, 2006, from $72,490 during the quarter ended
September 30, 2005.  This increase was due to equity based non-cash employee
compensation, acquisition related expenditures and increased employment
levels.

Nine Months Ended September 30, 2006 compared to Nine Months Ended September
30, 2005
--------

          Our revenues increased during the nine months ended September 30,
2006, to $1,907,540, from $1,628,313 for the nine months ended September 30,
2005, also primarily as a result of a general improvement in sales across
several product lines.

          Our cost of goods increased in the nine months ended September 30,
2006, as compared to September 30, 2005, to $1,177,137 from $919,883, also as
a result of increased raw material costs and increased sales.

          General and administrative expenses increased to $1,053,099 during
the nine months ended September 30, 2006, from $322,921 during the nine months
ended September 30, 2005.  This increase was due to equity based non-cash
employee compensation, acquisition related expenditures and increased
employment levels.

Liquidity and Capital Resources.
--------------------------------

          Our cash resources at September 30, 2006, were $113,653, with
accounts receivable of $447,160.  We sold 400,000 shares of our common stock
that are "restricted securities" as defined in Rule 144 to "accredited
investors" only, to finance the acquisition of JM SciTech, LLC.  These shares
were sold at a price of $0.80 per share.  None of these shares were accorded
registration rights of any kind.

          Subsequent to the quarter ended September 30, 2006, the Company sold
503,335 shares of its common stock that are "restricted securities" at $0.75
per share for aggregate consideration of $$377,501.25. These funds should be
adequate for the next 12 months for continuing operations; however, plans for
expansion will require additional capital of approximately $2,500,000.

Forward-Looking Statements.
---------------------------

         The Private Securities Litigation Reform Act of 1995 (the "Act")
provides a safe harbor for forward-looking statements made by or on behalf of
our Company.  Our Company and our representatives may from time to time make
written or oral statements that are "forward-looking," including statements
contained in this Quarterly Report and other filings with the Securities and
Exchange Commission and in reports to our Company's stockholders. Management
believes that all statements that express expectations and projections with
respect to future matters, as well as from developments beyond our Company's
control, including changes in global economic conditions are forward-looking
statements within the meaning of the Act. These statements are made on the
basis of management's views and assumptions, as of the time the statements are
made, regarding future events and business performance. There can be no
assurance, however, that management's expectations will necessarily come to
pass.  Factors that may affect forward-looking statements include a wide
range of factors that could materially affect future developments and
performance, including the following:

         Changes in Company-wide strategies, which may result in changes in
the types or mix of businesses in which our Company is involved or chooses to
invest; changes in U.S., global or regional economic conditions, changes in
U.S. and global financial and equity markets, including significant interest
rate fluctuations, which may impede our Company's access to, or increase the
cost of, external financing for our operations and investments; increased
competitive pressures, both domestically and internationally, legal and
regulatory developments, such as regulatory actions affecting environmental
activities, the imposition by foreign countries of trade restrictions and
changes in international tax laws or currency controls; adverse weather
conditions or natural disasters, such as hurricanes and earthquakes, labor
disputes, which may lead to increased costs or disruption of operations.

         This list of factors that may affect future performance and the
accuracy of forward-looking statements is illustrative, but by no means
exhaustive.  Accordingly, all forward-looking statements should be evaluated
with the understanding of their inherent uncertainty.

Item 3. Controls and Procedures.
--------------------------------

     As of the end of the period covered by this Quarterly Report, we carried
out an evaluation, under the supervision and with the participation of our
President and Secretary, of the effectiveness of the design and operation of
our disclosure controls and procedures. Based on this evaluation, our
President and Secretary concluded that information required to be disclosed is
recorded, processed, summarized and reported within the specified periods and
is accumulated and communicated to management, including our President and
Secretary, to allow for timely decisions regarding required disclosure of
material information required to be included in our periodic Securities and
Exchange Commission reports. Our disclosure controls and procedures are
designed to provide reasonable assurance of achieving their objectives and our
President and Secretary have concluded that our disclosure controls and
procedures are effective to a reasonable assurance level of achieving such
objectives. However, it should be noted that the design of any system of
controls is based in part upon certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in
achieving its stated goals under all potential future conditions, regardless
of how remote. In addition, we reviewed our internal controls over financial
reporting, and there have been no changes in our internal controls or in other
factors in the last fiscal quarter that has materially affected our internal
controls over financial reporting.

                        PART II - OTHER INFORMATION

Item 1.   Legal Proceedings.
----------------------------

          None; not applicable.

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds.
----------------------------------------------------------------------

          As of the quarter ended September 30, 2006, we issued 1,073,500
of our common stock for cash.

          We also issued 415,000 shares of our common stock for services and
53,675 shares of our common stock for introductory services.

          We issued all of these securities to persons who were "accredited
investors"; and each had prior access to all material information about us.
We believe that the offer and sale of these securities were exempt from the
registration requirements of the Securities Act of 1933, as amended (the
"Securities Act"), pursuant to Sections 4(2) and 4(6) thereof; and Rule 506 of
Regulation D of the Securities and Exchange Commission, under which state law
is preempted.

          Effective August 3, 2006, we signed a Letter of Intent to purchase
All Temp Engineering.  As consideration for the purchase, the Company will
issue 2,000,000 shares of its common stock that are restricted securities and
pay certain royalties to its shareholders.  As of September 30, 2006, the
purchase had not been completed.

          Effective August 23, 2006, we signed a Letter of Intent to  purchase
Smithgall & Associates, Inc., dba Image Labs International.  As consideration
for the purchase, the Company will issue 525,000 shares of its common stock
that are restricted securities; pay $200,000; pay certain royalties on certain
of Image Labs business segments to this shareholder; and will employ Image
Labs sole shareholder. Simultaneously, the Company signed another Letter of
Intent to employ another person associated with a business segment of Image
Labs; paid the associated person $37,500 on the signing of that Letter of
Intent; will pay that person certain royalties on another business segment of
Image Labs; and has agreed to issue 500,000 shares of its common stock that
are restricted securities. As of September 30, 2006, the purchase of Image
Labs had not yet been completed.

Item 3.   Defaults Upon Senior Securities.
------------------------------------------

          None; not applicable.

Item 4.   Submission of Matters to a Vote of Security Holders.
--------------------------------------------------------------

          None; not applicable.

Item 5.   Other Information.
----------------------------

          None; not applicable.

Item 6.   Exhibits.
-------------------

          Exhibits.

               31.1   302 Certification of Kim Boyce

               31.2   302 Certification of Kevin Cooksy

               32     906 Certification.

                               SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Quarterly Report to be signed on its
behalf by the undersigned thereunto duly authorized.

                                          REFLECT SCIENTIFIC, INC.

Date: 11/13/06                            /s/Kim Boyce
                                          ------------------------------------
                                          Kim Boyce, President

Date: 11/13/06                            /s/Tom Tait
                                          ------------------------------------
                                          Tom Tait, Vice President


Date: 11/13/06                            /s/Kevin Cooksy
                                          ------------------------------------
                                          Kevin Cooksy, Secretary/Treasurer
<PAGE>